Danaher’s $9.9B Masimo bid tests strategy with push into hospital monitoring
- Danaher is acquiring Masimo for $180 a share, expanding into hospital-focused patient monitoring.
- Danaher will fund with cash and debt; expects EPS accretion and long-term diagnostics growth acceleration.
- Deal departs from Danaher’s typical tuck‑ins, entering hospital hardware and paying a higher valuation multiple.
Danaher’s Masimo push tests medtech strategy
Main Topic — A push into hospital monitoring raises strategic questions
Danaher is moving to acquire Masimo for $180 a share in a deal that places Masimo’s enterprise value at about $9.9 billion, signaling a notable expansion of Danaher’s footprint into hospital-focused patient monitoring. The buyer says it will fund the transaction with cash and debt and expects the deal to be accretive to adjusted diluted net earnings per share by $0.15–$0.20 in the first full year and roughly $0.70 five years after close, while projecting Masimo will deliver high-single-digit core revenue growth over the long term and accelerate Danaher’s diagnostics growth.
The deal raises strategic and valuation questions because Masimo’s core products — pulse oximetry and bedside monitoring hardware aimed at hospitals — sit outside Danaher’s traditional mix of life-science tools and diagnostics platforms. Danaher values Masimo at about 18 times estimated 2027 EBITDA and aims to pare that multiple to roughly 15 times through cost and commercial synergies. Analysts note the acquisition departs from the company’s recent pattern of smaller, more familiar “tuck‑in” buys and represents a more transformative entry into medtech hardware and hospital systems.
Execution risk centers on integration and the ability to translate assumed synergies into sustained organic growth. Danaher is well known for reshaping businesses through acquisitions, most recently with the Abcam purchase, but integrating a hospital-device franchise requires different commercial channels, service models and regulatory navigation. Management’s ability to harmonize product portfolios, leverage diagnostics ties, and extract cost savings will determine whether the transaction meaningfully advances Danaher’s strategy beyond incremental revenue accretion.
Other relevant developments
The Masimo agreement follows a two‑year governance shift at Masimo after activist Politan Capital led a proxy contest that removed founder Joe Kiani as board chair. That governance change is now a proximate factor in the transaction, illustrating how activist campaigns and board reshuffles can accelerate strategic reviews and exit outcomes.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

